The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein—a well-known, yet poorly understood drug transporter
- 704 Downloads
P-glycoprotein is the most crucial membrane transporter implicated in tumor resistance. Intensive efforts were paid to elucidate the complex mechanism of transport and to identify modulators of this transporter. However, the borderline between substrates and modulators is very thin and identification of the binding sites within P-glycoprotein is complex. Herein, we provide an intensive review of those issues and use molecular docking to assess its ability: first, to differentiate between three groups (substrates, modulators and non-substrates) and second to identify the binding sites. After thorough statistical analysis, we conclude despite the various challenges that molecular docking should not be underestimated as differences between the distinct groups were significant. However, when it comes to defining the binding site, care must be taken, since consensus throughout literature could not be reached.
KeywordABC transporter Cancer Chemotherapy Multidrug resistance
There is no conflict of interest. We are grateful to the German Academic Exchange Service (DAAD) and the National Research Institute, Sudan for stipends to M.Z. and M.E.M. S., respectively, as well as to the Johannes University, Mainz for an intramural PhD position to O.K.
- 2.Katzung BG (2007) Basic and Clinical Pharmacology. 10th edition, p 879.Google Scholar
- 3.Andreoli TE, Bennet JC, Carpenter CCJ, Plum F (1997) Cecil Essentials of Medicine. 4th edition, p 425.Google Scholar
- 7.Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, Fojo T, Bates SE (2008) Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)- mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol 75:1302–12PubMedCentralCrossRefPubMedGoogle Scholar
- 8.Leitner I, Nemeth J, Feurstein T, Abrahim A, Matzneller P, Lagler H, Erker T, Langer O, Zeitlinger M (2011) The third-generation P-glycoprotein inhibitor tariquidar may overcome bacterial multidrug resistance by increasing intracellular drug concentration. J Antimicrob Chemother 66:834–9CrossRefPubMedGoogle Scholar
- 9.Coley HM (2010) Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. In Multi-Drug Resistance in Cancer, Humana Press, pp. 341–358.Google Scholar
- 10.Holland IB, Cole SPC, Kuchler K, Higgens CF (2003) ABC proteins: from bacteria to man. Elsevier Science, London, 251Google Scholar
- 26.Bolton E, Wang Y, Thiessen PA, Bryant SH (2008) PubChem: integrated platform of small molecules and biological activities. Chapter 12 IN annual reports in computational chemistry, volume 4. American Chemical Society, WashingtonGoogle Scholar
- 28.Tajima Y, Nakagawa H, Tamura A, Kadioglu O, Satake K, Mitani Y, Murase H, Regasini LO, da Silva Bolzani V, Ishikawa T, Fricker G, Efferth T (2013) Nitensidine A, a guanidine alkaloid from Pterogyne nitens, is a novel substrate for human ABC transporter ABCB1. Phytomedicine [Epub ahead of print]Google Scholar
- 29.Zeino M, Zhao Q, Eichhorn T, Hermann J, Müller R, Efferth T (2013) Molecular docking studies of myxobacterial disorazoles and tubulysins to tubulin. J Biosci Med 3:31–43Google Scholar
- 30.Hartmann J (2000) Choosing the correct statistical test. University of Alabama, USA, http://bama.ua.edu/~jleeper/627/choosestat.html, last retrieved: 12.12.2013.Google Scholar